SCHEMBL31668618

CC(=O)N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)O[C@H](CO[C@]2(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O2)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O[C@]2(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O2)[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.75

▸	MAG	P20916	9/20	0.68

▸	SELL	P14151	1/20	0.61

▸	SELP	P16109	1/20	0.61

▸	SELE	P16581	3/20	0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30650503	0.99	SIGLEC7 (0.74)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31701080	0.99	SIGLEC7 (0.74)	SIGLEC7MAGSELLSELPSELE
SCHEMBL29615770	0.99	SIGLEC7 (0.73)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31717035	0.99	SIGLEC7 (0.73)	SIGLEC7MAGSELLSELPSELE
SCHEMBL12472427	0.99	SIGLEC7 (0.73)	SIGLEC7MAGSELLSELPSELE
SCHEMBL30652057	0.99	SIGLEC7 (0.73)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31717400	0.99	SIGLEC7 (0.73)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31701686	0.98	SIGLEC7 (0.72)	SIGLEC7MAGSELLSELPSELE
SCHEMBL30970744	0.97	SIGLEC7 (0.75)	SIGLEC7MAGSELLSELPSELE
SCHEMBL30427944	0.97	SIGLEC7 (0.71)	SIGLEC7MAGSELLSELPSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250319190-A1	APOE LIPOPROTEIN SYSTEMS	KISBEE THERAPEUTICS INC (US)	2025-10-16	—	—	US	disclosed
US-20250242035-A1	GLYCAN CONJUGATE COMPOSITIONS AND METHODS	GANNA BIO, INC.	2025-07-31	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250319190-A1	APOE LIPOPROTEIN SYSTEMS	APOB, APOL1, LDLR	SIGLEC7 692/4885MAG 918/4885SELL 156/4885
US-20250242035-A1	GLYCAN CONJUGATE COMPOSITIONS AND METHODS	SIGLEC7, SIGLEC9, ENGASE	SIGLEC7 1/4885MAG 343/4885SELL 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.